Page last updated: 2024-12-07

beta-neo-endorphin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Beta-neo-endorphin is a naturally occurring opioid peptide that is produced in the pituitary gland. It is a potent analgesic and has been shown to have a variety of other effects, including anti-inflammatory, antidepressant, and anxiolytic effects. Beta-neo-endorphin is a derivative of pro-opiomelanocortin (POMC), a large precursor protein that is also cleaved to produce other opioid peptides, such as endorphin and ACTH. Beta-neo-endorphin is synthesized by the body and released in response to stress, pain, and other stimuli. It is then transported to the brain and other organs, where it binds to opioid receptors and produces its effects. It is a potent analgesic, meaning it can reduce pain. This effect is thought to be mediated by its binding to opioid receptors in the brain. It has been shown to have anti-inflammatory effects. This effect may be due to its ability to inhibit the release of pro-inflammatory cytokines. It has been shown to have antidepressant and anxiolytic effects. These effects are thought to be mediated by its binding to opioid receptors in the brain. Research on beta-neo-endorphin aims to understand its role in pain, inflammation, mood, and other physiological processes. This research may lead to the development of new drugs to treat pain, depression, anxiety, and other conditions.'

beta-neo-endorphin: nonapeptide opioid of porcine origin with amino acid sequence Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro which is the C-terminal deleted peptide from alpha-neo-endorphin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122260
SCHEMBL ID14889478
MeSH IDM0096960

Synonyms (18)

Synonym
gtpl1644
big leu-enkephalin
beta-neoendorphin
77739-21-0
(2s)-1-[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-
bdbm82082
cb0758529
cas_77739-21-0
beta-neo-endorphin
alpha-neoendorphin, 10-de-l-lysine-
SCHEMBL14889478
b-neoendorphin
mfcd00076401
Q4897190
MS-31959
DTXSID401029639
CS-0615337
HY-P3513
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346329Human kappa receptor (Opioid receptors)1995Proceedings of the National Academy of Sciences of the United States of America, Jul-18, Volume: 92, Issue:15
kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system.
AID1346411Rat kappa receptor (Opioid receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Nov-01, Volume: 90, Issue:21
Cloning and pharmacological characterization of a rat kappa opioid receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (80.77)18.7374
1990's5 (19.23)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.87 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]